Please assess the completion status of the following clinical trial:

Trial Title: Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female of non-childbearing potential between 18 and 65 years of age inclusive.~2. Presence of mild-to-moderately active ulcerative colitis spread beyond the rectum as evidenced by clinical signs and endoscopy.~3. UCDAI score 4-10 (inclusive) with rectal bleeding score ≥ 1, endoscopy score ≥ 1 and Physician's rating of disease activity \< 3.~4. Body weight \> or = to 50 kg and BMI within the range 18.5-29.9 kg/m2 (inclusive).~5. Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form~Exclusion Criteria:~1. History of sensitivity to any component of study medications, history of hypersensitivity to ACTH, or a history of drug or other allergy that, in the opinion of the Investigator, contraindicates patient's participation in the study.~2. History of renal sensitivity to 5-ASA or presence of nephritis, nephropathia or renal function impairment.~3. Presence or a history of asthma or presence or history of other serious allergic disorder.~4. Presence or history of chronic liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).~5. A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.~6. Presence of significant hematologic disorder, or significant bleeding or immune system disorder.~7. QTcB or QTcF \>450 msec; or QTc \>480 msec in patients with Bundle Branch Block, based on an average QTc value of triplicate ECGs, if the first ECG showed an abnormal value.~8. Presence of a significant cardiac, pulmonary, metabolic or infectious disease or mental disorder that, in the opinion of the Investigator, represents an unacceptable safety risk for participation in this trial.~9. History of malignant neoplastic disease within the past 5 years other than localized basal cell skin cancer, squamous cell skin cancer or cancer in situ that has been resected.~10. History of regular alcohol consumption within 6 months of the study or presence of recreational drug abuse or dependence.~11. Presence of infectious colitis as evidenced by stool culture positive for enteric pathogens or positive Clostridium difficile cytotoxin assay.~12. Suspicion of Crohn's disease, indeterminate colitis, microscopic colitis, ischaemic colitis or radiation-induced colitis, based on medical history, endoscopy and/or histological findings.~13. Bowel surgery within last 12 months.~14. Treatment with oral aminosalicylates at dose ≥ 2.4 g/day and/or with topical aminosalicylates at any dose within 2 weeks prior to Day 1 visit.~15. Treatment with systemic or topical corticosteroids within 4 weeks prior to Day 1 visit.~16. Treatment with TNF-α inhibitors or other biologics within 2 months prior to Day 1 visit.~17. Treatment with immunosuppressants (azathioprine or 6-mercaptopurine), if initiated within 3 months prior to Day 1 visit, or if changed in terms of drug or dose within 3 months prior to Day 1 visit.~18. Regular use of probiotic or prebiotic preparations, if initiated within 4 weeks prior to Day 1 visit.~19. Regular daily use of non-steroidal anti-inflammatory drugs (NSAIDs), except low dose aspirin (325 mg/day) for cardioprotection, within 7 days prior to Day 1 visit.~20. Treatment with medications known to be strong inducers of CYP3A4/5 (e.g. carbamezipine, phenobarbital, phenytoin, rifabutin, rifampin, troglitazone) or regular use of St. John's Wort within 14 days prior to Day 1 visit.~21. Treatment with medications known to be strong inhibitors of CYP3A4/5 (e.g. ketoconazole, itraconazole, fluconazole, mibefradil, clarithromycin, erythromycin, diltiazem, verapamil), or regular use of grapefruit juice within 7 days prior to Day 1 visit.~22. Treatment with medications known to be sensitive CYP3A4 substrates with a narrow therapeutic index (e.g. alfentanil, astemizole, cisapride, cyclosporine, diergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, terfenadine) within 7 days prior to Day 1 visit.~23. Participation in a clinical trial and treatment with an investigational product within the following time period prior to the Day 1 visit: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).~24. Prior enrolment in the present trial.~    For Canadian sites only:~25. Patients with existing gastric or duodenal ulcers.~26. Patients with urinary tract obstruction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group 2 (Type: EXPERIMENTAL): ASACOL 800mg t.i.d.
- Group 1 (Type: EXPERIMENTAL): GSK1399686 at 3-4 dose levels
- Group 3 (Type: EXPERIMENTAL): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete